Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer

Published:2017-03-08 Issue:3 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Shepherd Andrew RH¹²,Shepherd Emily³,Brook Nicholas R¹²

Affiliation:

1. Royal Adelaide Hospital; Department of Urology; North Terrace Adelaide South Australia Australia 5000

2. The University of Adelaide; School of Medicine; Adelaide Australia

3. The University of Adelaide; ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology; Adelaide South Australia Australia 5006

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012112.pub2/epdf/full

Reference80 articles.

1. BCG vs BCG plus recombinant Alfa-Interferon 2b for superficial bladder TCC;Bercovich;Archivio Italiano Di Urologia e Andrologia,1995

2. BCG Pasteur F and recombinant interferon alpha 2b in the prophylaxis of recurrent superficial neoplasia of the bladder: Preliminary results of a randomized study;Irianni;Acta Urologica Italica,1993

3. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer;Chiong;European Urology,2011

4. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha;Esuvaranathan;Cancer,2007

5. Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer;Esuvaranathan;BJU International,2014

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer;Minerva Urology and Nephrology;2024-07

2. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer;Expert Opinion on Biological Therapy;2024-06-02

3. Documento multidisciplinar de consenso sobre el tratamiento actual del tumor vesical no-músculo invasor que no responde al tratamiento con bacilo Calmette-Guérin;Actas Urológicas Españolas;2024-05

4. Perfusion drugs for non‑muscle invasive bladder cancer (Review);Oncology Letters;2024-04-15

5. BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer;Current Oncology;2024-02-16